News

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

BIO-CAT, Inc., an industry leading probiotic manufacturer, has agreed to partner with global distribution solutions provider Caldic North America to bring their proprietary probiotic strains and OPTIFEED® branded solutions to the Companion Animal Health and Nutrition market in North America. This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic’s leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.

Founded in Keswick, Virginia, BIO-CAT is an industry-leading expert in specialty enzyme and probiotic formulations. The company offers an extensive range of single-to-multi-enzyme blends and unique microbial solutions for better animal digestive health. BIO-CAT Microbials, located in Shakopee Minnesota, is BIO-CAT’s vertically integrated FDA registered and SQF certified (human-grade) U.S. fermentation facility. Their AAFCO-listed OPTIFEED® probiotic strains are premium, safe, effective, and have shown physiological benefits to companion animals in support of their gastrointestinal and digestive health; similar to the benefits they deliver to humans. Future expansion of the OPTIFEED® line of enzymes will further support digestive health, enhancing the nutritional value of pet food, and can be used in ingredient processing and flavor development.

“This partnership with BIO-CAT significantly strengthens Caldic’s existing Companion Animal portfolio,” says Liz Parker, Director of Companion Animal Health & Nutrition, Caldic North America, “adding a range of innovative and customizable solutions to inspire quality pet food and health. As the importance of pet companionship is widely recognized, domestic animal owners are increasingly keen to provide their pets with nutritionally high-performing food, treats and supplements. The expert know-how our R&D team has acquired in pet food when formulating with our antioxidants range, Dadex®, and our custom vitamin and mineral blends, Daminaide®, will greatly benefit the solutions we can deliver across North America while partnering with BIO-CAT.”

“BIO-CAT Microbials’ expertise in probiotic strain development and fermentation is a great match for Caldic’s exceptional distribution solutions,” says Chris Schuler, President and CEO of BIO-CAT. “We value Caldic’s commitment to the Companion Animal space and their ability to scale our OPTIFEED® probiotic business within their customer base. We look forward to a successful collaboration and exclusive partnership with Caldic.”

Recent News

03/21/2025

Luna Labs to Expand Research and Development Operations in Charlottesville

Governor Glenn Youngkin today announced that Luna Labs USA, LLC, a product development company accelerating breakthrough solutions to multiple industries, will invest $200,000 to expand its operations in the City of Charlottesville. The company will create 20 new jobs. “Luna Labs’ expansion demonstrates Virginia’s ability to cultivate and retain innovative technology companies,” said Governor Glenn Youngkin.

03/18/2025

Committed to Innovation: Roanoke Blacksburg Innovation Alliance Replaces Verge

The Roanoke Blacksburg Innovation Alliance, formerly Verge, unveiled a major rebrand to reflect their ongoing commitment to tech-based economic advancement and their leadership in a portfolio of organizations dedicated to developing the Roanoke Blacksburg innovation ecosystem. The elements of the Roanoke Blacksburg Innovation Alliance (RBIA) include: A new name that reflects the commitment of Roanoke Blacksburg

03/14/2025

CEL-SCI’s Head and Neck Cancer Study Clears FDA Review, Eyes Commercialization Partners

CEL-SCI Corporation announced that a third-party study published on March 6, 2025 in JAMA Oncology titled “Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Non-randomized Clinical Trial” provided data that support Multikine’s use as a neoadjuvant treatment in patients with tumors having low PD-L1 expression